Prognostic and predictive value of metastatic lymph node ratio in stage III gastric cancer after D2 nodal dissection

Yinbo Chen(Zhejiang Cancer Hospital), Cong Luo(Central South University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Cong Li(Zhejiang Cancer Hospital), Yian Du(Zhejiang Cancer Hospital), Qi Xu(China Jiliang University)
Oncotarget
August 7, 2017
10.18632/oncotarget.19998
Cited by 6

Related Papers

Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384